Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
kidney transplant
Biotech
Memo pushes kidney drug to phase 3 despite primary endpoint miss
A phase 2 trial of Memo’s kidney transplant drug candidate has missed its primary endpoint, adding to the list of setbacks in the indication.
Nick Paul Taylor
Jul 25, 2025 5:30am
Paragonix's donor organ perfusion system flies kidney commercial
Mar 3, 2025 12:06pm
eGenesis announces 2nd pig kidney transplant success
Feb 7, 2025 2:10pm
Northwestern surgeons transplant kidney into fully awake patient
Jun 25, 2024 2:23pm
Cell therapy allows kidney recipients to cut immunosuppressants
Nov 2, 2023 10:00am
United Therapeutics buys Miromatrix in $91M xenotransplant deal
Oct 30, 2023 10:45am
